News >

Durvalumab Being Explored in Real-World Setting of Locally Advanced Stage III NSCLC

Danielle Ternyila
Published: Monday, May 20, 2019

Nicolas Girard, MD
Nicolas Girard, MD
Following its FDA approval for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy, durvalumab (Imfinzi) is now being explored in the real-world setting, explained Nicolas Girard, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication